UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549

                                   FORM 10-QSB
(Mark One)

[X]      QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
         EXCHANGE ACT OF 1934

For the quarterly period ended    December 31, 2003

[]       TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
         EXCHANGE ACT OF 1934

For the transition period from ________________ to _______________

Commission File No.     33-55254-09

                        Rocky Point Pharmaceuticals, Inc.
        (Exact name of Small Business Issuer as specified in its charter)

         NEVADA                                      87-0434293
(State or other jurisdiction of             (I.R.S. Employer
incorporation or organization)       Identification Number)

9350 South 150 East, Suite 900
         Sandy, Utah                           84070
(Address of principal executive offices)    (Zip Code)

Issuer's telephone number, including area code      (801) 617-2040

     Indicate  by check  mark  whether  the  Issuer  (1) has filed  all  reports
required to be filed by Section 13 or 15(d) of the  Securities  Exchange  Act of
1934 during the preceding 12 months (or for such shorter  period that the Issuer
was  required  to file such  reports),  and (2) has been  subject to such filing
requirements for the past 90 days. [X] Yes [ ] No

     Indicate the number of shares  outstanding of each of the Issuer's  classes
of common stock, as of the latest practicable date.

             Class                       Outstanding as of December 31, 2003
$.001 PAR VALUE CLASS A COMMON STOCK              13,069,000 SHARES

                                        1
<PAGE>

                         PART 1 - FINANCIAL INFORMATION

Item 1.  Financial Statements.

BASIS OF REPRESENTATION

General

     The  accompanying  unaudited  financial  statements  have been  prepared in
accordance with the instructions to Form 10-QSB and,  therefore,  do not include
all information and footnotes necessary for a complete presentation of financial
position,  results of  operations,  cash flows and  stockholders'  (deficit)  in
conformity  with generally  accepted  accounting  principles.  In the opinion of
management,  all adjustments considered necessary for a fair presentation of the
results of  operations  and  financial  position have been included and all such
adjustments  are of a normal  recurring  nature.  Operating  results for the six
months ended  December 31, 2003, are not  necessarily  indicative of the results
that can be expected for the year ending June 30, 2004.


                                        2
<PAGE>

                        Rocky Point Pharmaceuticals, Inc.
                          (A Development Stage Company)
                                 BALANCE SHEETS


<TABLE>
<CAPTION>
                                                                       December 31,                 June 30,
                                                                           2003                       2003
                                                                        (Unaudited)                 (Audited)
                                                                  ----------------------     --------------------
ASSETS
   CURRENT ASSETS
<S>                                                               <C>                        <C>
     Cash in bank                                                 $                    0     $                  0
     Accounts receivable                                                              69                        0
                                                                  ----------------------     --------------------
     Prepaid expenses                                                              2,000                        0

                                          TOTAL CURRENT ASSETS    $                2,069     $                  0

LIABILITIES & (DEFICIT)
   CURRENT LIABILITIES
     Accounts payable                                             $                    0     $                900
     Payable - related parties (Note 4)                                            3,701                      801
                                                                  ----------------------     --------------------

                                     TOTAL CURRENT LIABILITIES                     3,701                    1,701

   STOCKHOLDERS' EQUITY (DEFICIT)
     Common Stock $.001 par value:
       Authorized - 100,000,000 shares
       Issued and outstanding 13,069,000 and
         13,000,000 shares, respectively (Note 5)                                 13,069                   13,000
     Deficit accumulated during the
       development stage                                                         (14,701)                 (14,701)
                                                                  ----------------------     --------------------

                                          TOTAL STOCKHOLDERS'
                                              EQUITY (DEFICIT)                    (1,632)                  (1,701)
                                                                  ----------------------     --------------------

                                                                  $                2,069     $                  0
                                                                  ======================     ====================
</TABLE>


                                        See Notes to Financial Statements.

                                                         3
<PAGE>

                        Rocky Point Pharmaceuticals, Inc.
                          (A Development Stage Company)
                            STATEMENTS OF OPERATIONS
                                   (Unaudited)



<TABLE>
<CAPTION>
                                                                                                                      4/14/1986
                                                   Three Months Ended                  Six Months Ended               (Date of
                                                      December 31,                       December 31,               inception) to
                                                 2003              2002             2003              2002           12/31/2003
                                            --------------    -------------     -------------    -------------     ---------------
<S>                                         <C>               <C>               <C>              <C>               <C>
Net sales                                   $            0    $           0     $           0    $           0     $             0
Cost of sales                                            0                0                 0                0                   0
                                            --------------    -------------     -------------    -------------     ---------------

                              GROSS PROFIT               0                0                 0                0                   0

General and administrative expenses                      0            1,150                 0            2,200              15,501
                                            --------------    -------------     -------------    -------------     ---------------
                                                         0            1,150                 0            2,200              15,501

OTHER INCOME
   Gain on sale of subsidiary                            0                0                 0                0                 800
                                            --------------    -------------     -------------    -------------     ---------------

                                  NET LOSS  $            0    $      (1,150)    $           0    $      (2,200)    $       (14,701)
                                            ==============    =============     =============    =============     ===============

Basic and Diluted Earnings per Share
   Net (loss) per weighted average share    $          .00    $        (.00)    $         .00    $        (.00)
                                            ==============    =============     =============    =============

Weighted average number of common
   shares used to compute net income (loss)
   per weighted average share                   13,069,000       14,122,285        13,060,750       13,549,841
                                            ==============    =============     =============    =============

</TABLE>


                       See Notes to Financial Statements.

                                        4
<PAGE>

                        Rocky Point Pharmaceuticals, Inc.
                          (A Development Stage Company)
                            STATEMENTS OF CASH FLOWS
                                   (Unaudited)



<TABLE>
<CAPTION>
                                                                                                                      4/14/1986
                                                   Three Months Ended                  Six Months Ended               (Date of
                                                      December 31,                       December 31,               inception) to
                                                 2003              2002             2003              2002           12/31/2003
                                            --------------    -------------     -------------    -------------     ---------------
OPERATING ACTIVITIES
<S>                                         <C>               <C>               <C>              <C>               <C>
   Net income (loss)                        $            0    $      (1,150)    $           0    $      (2,200)    $       (14,701)
   Adjustments to reconcile net income
     (loss) to cash used by operating
     activities:
       Amortization                                      0                0                 0                0                  50
       Stock issued for expenses                         0                0                 0                0              12,000
       Changes in accounts payable                       0              550              (900)          (1,100)                  0
       Changes in accounts receivable                    0                0               (69)               0                 (69)
       Changes in prepaid expenses                  (2,000)               0            (2,000)               0              (2,000)
       Payable - related parties                     2,000              600             2,900           (3,200)              2,701
                                            --------------    -------------     -------------    -------------     ---------------

                          NET CASH USED BY
                      OPERATING ACTIVITIES               0                0               (69)          (6,500)             (2,019)

INVESTING ACTIVITIES
   Organization costs                                    0                0                 0                0                 (50)
                                            --------------    -------------     -------------    -------------     ---------------

                           NET PROVIDED BY
                      INVESTING ACTIVITIES               0                0                 0                0                 (50)

FINANCING ACTIVITIES
   Issuance of common stock                              0                0                69            7,699               2,069
                                            --------------    -------------     -------------    -------------     ---------------

                         NET CASH PROVIDED
                   BY FINANCING ACTIVITIES               0                0                69            7,699               2,069

               INCREASE (DECREASE) IN CASH
                      AND CASH EQUIVALENTS               0                0                 0            1,199                   0

Cash and cash equivalents
   at beginning of period                                0            1,199                 0                0                   0
                                            --------------    -------------     -------------    -------------     ---------------

                   CASH & CASH EQUIVALENTS
                          AT END OF PERIOD  $            0    $       1,199     $           0    $       1,199     $             0
                                            ==============    =============     =============    =============     ===============
</TABLE>


ADDITIONAL INFORMATION

     A payable of $1,000 was settled by issuing 1,000,000 shares of common stock
     to the note holder. Shares were issued at par on August 27, 2002.


                       See Notes to Financial Statements.

                                        5
<PAGE>

                        Rocky Point Pharmaceuticals, Inc.
                          (A Development Stage Company)
                          NOTES TO FINANCIAL STATEMENTS
                                December 31, 2003


NOTE 1:       CHANGE IN REPORTING ENTITY

          The statement of operations  reflects the  acquisition  of Rocky Point
          Pharmaceuticals,  Inc.  ("Rocky Point") a reporting  company under the
          Securities Act of 1934, by Luong Dae Solutions,  Inc.,("Luong  Dae") a
          development-stage  company, on June 26, 2002 in a reverse acquisition,
          consummated  by  issuing  11,000,000  shares of common  stock of Rocky
          Point to the founders of Luong Dae. Reverse acquisition  accounting is
          appropriate   since  the   shareholders   of  Luong   Dae   controlled
          approximately  92% of the  outstanding  common  stock of  Rocky  Point
          immediately  after  the  acquisition,  and  management  of  Luong  Dae
          controlled  the board of directors  and  day-to-day  management of the
          Company after the acquisition.  The reverse acquisition  constitutes a
          change in  reporting  entity for  accounting  purposes.  This  reverse
          acquisition is considered to be a capital  transaction (i.e.  issuance
          of  stock by  Rocky  Point  accompanied  by a  recapitalization).  The
          historical  financial statements reflect the assets and liabilities of
          Luong Dae at their  historical  cost. Rocky Point had no assets on the
          date of the reverse acquisition. Rocky Point had liabilities of $7,550
          on the date of the reverse acquisition.

          At March  31,  2003,  the  Company  sold its  interest  in Loung  Dae.
          Previous financial  statements of the Company captioned  "Consolidated
          Financial Statements" presented the financial condition of the Company
          together with that of Luong Dae, then a  majority-owned  subsidiary of
          the Company,  on a consolidated  basis.  The disposal of the Company's
          interest  in  Luong  Dae,   which  had  no  material   net  assets  or
          liabilities,  had no direct actual  impact on the financial  condition
          resulting from the de-consolidation of Luong Dae.

NOTE 2:   SUMMARY OF SIGNIFICANT ACCOUNTING PRINCIPLES

          Accounting Methods:

          The Company recognizes income and expenses based on the accrual method
          of accounting.

          Dividend Policy:
          The  Company  has not yet  adopted  any  policy  regarding  payment of
          dividends.

          Cash and Cash Equivalents:
          For financial  statement  purposes,  the Company  considers all highly
          liquid  investments with an original  maturity date of three months or
          less when purchased to be cash equivalents.

          Estimates:
          The  preparation of financial  statements in conformity with generally
          accepted  accounting  principles requires management to make estimates
          and   assumptions   that  affect  the  reported   amounts  of  assets,
          liabilities,  revenues  and  expenses  during  the  reporting  period.
          Estimates  also  affect  the  disclosure  of  contingent   assets  and
          liabilities  at the date of the financial  statements.  Actual results
          could differ from these statements.

          Net Loss Per Share:
          Basic and diluted  loss per share is  computed  by  dividing  net loss
          available to common  shareholders  by the weighted  average  number of
          common shares outstanding during the periods presented.

          Income Taxes:
          The Company  utilizes the liability  method of  accounting  for income
          taxes as set forth in Statement of Financial  Accounting Standards No.
          109,  "Accounting  for Income  Taxes" (SFAS 109).  Under the liability
          method,  deferred taxes are determined based on the difference between
          the financial  statement and tax bases of assets and liabilities using
          enacted tax rates in effect in the years in which the  differences are
          expected to  reverse.  An  allowance  against  deferred  tax assets is
          recorded  when it is more likely than not that such tax benefits  will
          not be realized.

                                        6
<PAGE>

                        Rocky Point Pharmaceuticals, Inc.
                          (A Development Stage Company)
                    NOTES TO FINANCIAL STATEMENTS (continued)
                                December 31, 2003



NOTE 2:       SUMMARY OF SIGNIFICANT ACCOUNTING PRINCIPLES

          At June 30, 2003 a deferred  tax asset of about  $4,700 has been fully
          reserved due to the Company's  lack of operations to provide income to
          use the net  operating  loss  carryover  of $13,900  which  expires as
          follows:

           Year Ended                    Expires                 Amount
          June 30, 2002               June 30, 2022           $          11,000
          June 30. 2003               June 30, 2023                       2,900
                                                              -----------------
                                                              $          13,900
                                                              =================

NOTE 3:       DEVELOPMENT STAGE COMPANY

          The Company was  originally  incorporated  as Upsilon,  Inc. under the
          laws of the  State  of Utah on  April  14,  1986  and has  been in the
          development  stage since  incorporation.  On December  30,  1993,  the
          Company was  dissolved as a Utah  corporation  and  reincorporated  in
          Nevada as Upsilon  Industries,  Inc.  On July 21,  1995,  the  Company
          changed  its name to TTN  Capitol,  Inc.,  on October  15,  1995,  the
          Company changed its name to Wasatch  Pharmaceutical,  Inc., and on May
          31, 2000 the Company changed its name to Rocky Point  Pharmaceuticals,
          Inc.  Luong Dae was  incorporated  on April 14,  1986 in  Nevada,  and
          became a  subsidiary  of the Company on June 26,  2002.  Luong Dae was
          disposed of on March 31, 2003.

NOTE 4:       RELATED PARTY TRANSACTIONS

          The Company neither owns nor leases any real property. Office services
          are provided, without charge, by an officer. Such costs are immaterial
          to the financial statements, and, accordingly, have not been reflected
          therein.  The  officers  and  directors of the Company are involved in
          other business  activities and may, in the future,  become involved in
          other  business  opportunities.  If a  specific  business  opportunity
          becomes  available,  such  persons  may face a conflict  in  selecting
          between the Company and their other  business  interests.  The Company
          has not formulated a policy for the resolution of such  conflicts.  At
          December  31,  2003 the  Company  owes  $3,701  to a  shareholder  for
          expenses paid on behalf of the Company.

NOTE 5:       COMMON STOCK

          On July 22, 2003,  69,000  shares of  Regulation S stock was issued at
          par. The Company recorded a receivable of $69 on that date.

NOTE 6:       GOING CONCERN ITEMS

          The financial  statements  are presented on the basis that the Company
          is a going concern,  which  contemplates the realization of assets and
          the  satisfaction of liabilities in the normal course of business over
          a reasonable  length of time. At December 31, 2003, the Company has no
          assets and all its expenses are being paid by its CEO. The Company has
          a substantial need for working capital.

          Management feels that loans from related parties and issuance of stock
          will  provide  sufficient  working  capital  to allow the  Company  to
          continue as a going concern.

                                        7
<PAGE>

Item 2.  Management's Discussion and Analysis of Financial Condition and Results
         of Operations

     The  Company  has had no  operational  history  and has  yet to  engage  in
business of any kind.  All risks inherent in new and  inexperienced  enterprises
are inherent in the Company's business.  The Company has not made a formal study
of the economic potential of any business.  At the present,  the Company has not
identified  any  assets or  business  opportunities  for  acquisition.  The only
activity for the period  ended  December  31, 2003 was the  incurrence  of costs
associated with periodic filings of required forms with the SEC.

     The Company has no liquidity and no presently  available capital resources,
such as credit lines, guarantees,  etc. and should a merger or acquisition prove
unsuccessful,  it is possible  that the Company may be dissolved by the State of
Nevada for  failing to file  reports.  Should  management  decide not to further
pursue its acquisition activities, management may abandon its activities and the
shares of the Company would become worthless.

     Based on current economic and regulatory  conditions,  Management  believes
that it is possible,  if not probable,  for a company like the Company,  without
many assets or liabilities,  to negotiate a merger or acquisition  with a viable
private company.  The opportunity arises  principally  because of the high legal
and  accounting  fees and the length of time  associated  with the  registration
process of "going public". However, should any of these conditions change, it is
very possible that there would be little or no economic  value for anyone taking
over control of the Company.

                           PART II - OTHER INFORMATION

Item 6.    Exhibits and Reports on Form 8-K

           (a)  Exhibits
                Exhibit 99.1 CEO Certification
                Exhibit 99.2 CFO Certification

           (b)  Reports on Form 8-K
                None.

                                   SIGNATURES

     Pursuant to the  requirements  of the  Securities and Exchange Act of 1934,
the  Issuer  has duly  caused  this  report to be  signed  on its  behalf by the
undersigned thereunto duly authorized.

                           Rocky Point Pharmaceuticals, Inc.


Dated: March 15, 2004      By:/s/ Mark Timothy
                           Mark Timothy, Acting President and Director

     Pursuant to the  requirements of the Securities  Exchange Act of 1934, this
report  has  been  signed  below  by the  following  persons  on  behalf  of the
registrant and in the capacities and on the dates indicated.


Dated:  March 15, 2004      By:  /s/ Mark Timothy
                            Mark Timothy, Acting President and Director


                                        8
<PAGE>

                                 Certifications

I, Mark Timothy certify that:

1.   I have  reviewed  this  quarterly  report  on Form  10-QSB  of Rocky  Point
     Pharmaceuticals, Inc.;

2.   Based on my knowledge,  this  quarterly  report does not contain any untrue
     statements of a material fact or omit to state a material fact necessary to
     make the statements  made, in light of the  circumstances  under which such
     statements  were made, not misleading with respect to the period covered by
     this quarterly report;

3.   Based on my  knowledge,  the  financial  statements,  and  other  financial
     information  included  in this  quarterly  report,  fairly  present  in all
     material respects the financial condition,  results of operations, and cash
     flows of the  registrant  as of, and for,  the  periods  presented  in this
     quarterly report;

4.   I am responsible for establishing and maintaining  disclosure  controls and
     procedures  (as defined in Exchange Act Rules  13a-15(e) and 15d-15(e)) for
     the registrant and have:

     a.   Designed  such  disclosure  controls  and  procedures  to ensure  that
          material  information  relating to the registrant  particularly during
          the period in which this quarterly report is being prepared;

     b.   Evaluated the  effectiveness of the registrant's  disclosure  controls
          and procedures and presented in this report our conclusions  about the
          effectiveness of the disclosure controls and procedures, as of the end
          of the period covered by this report based on such evaluations; and

     c.   Disclosed  in this  report any  changes in the  registrant's  internal
          control over financial reporting that occurred during the registrant's
          most recent fiscal quarter (the registrant's  fourth fiscal quarter in
          the case of an annual  report)  that has  materially  affected,  or is
          reasonably  likely to materially  affect,  the  registrant's  internal
          control over financial reporting; and

5.   I have disclosed,  based on my most recent evaluation,  to the registrant's
     auditors and  registrant's  board of directors (or persons  performing  the
     equivalent functions):

     a.   All significant  deficiencies and material weaknesses in the design or
          operation  of internal  control  over  financial  reporting  which are
          reasonably  likely to  adversely  affect the  registrant's  ability to
          record, process, summarize and report financial information; and

     b.   Any fraud, whether or not material,  that involves management or other
          employees who have a  significant  role in the  registrant's  internal
          control over financial reporting.


Date:  March 15, 2004

/s/ Mark Timothy
Mark Timothy, Acting President,
CEO, CFO, and Director


                                        9

<PAGE>

                    CERTIFICATION OF CHIEF FINANCIAL OFFICER
                                   PURSUANT TO
                             18 U.S.C. SECTION 1350,
                             AS ADOPTED PURSUANT TO
                  SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002


I, Mark  Timothy,  certify,  pursuant  to 18 U.S.C.  Section  1350,  as  adopted
pursuant to Section 906 of the Sarbanes-  Oxley Act of 2002,  that the Quarterly
Report on Form 10QSB of Rocky  Point  Pharmaceuticals,  Inc.  for the  quarterly
period ending December 31, 2003 fully complies with the  requirements of Section
13(a) or 15(d) of the Securities  Exchange Act of 1934 and that the  information
contained in the Quarterly  Report on Form 10QSB fairly presents in all material
respects  the  financial  condition  and  results of  operations  of Rocky Point
Pharmaceuticals, Inc.


                           By:

Date:  March 15, 2004           /s/ Mark Timothy
                           Mark Timothy
                           Chief Financial Officer


                                       10